Stockholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2017 |
|---|
| Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
|
| Share Based Compensation Stock Options, and Other Types of Grants of Stock Option |
The table below provides a summary of those plans as of December 31, 2017: | Fortress Company | | Stock Plan | | Shares Authorized | | Shares
available at
December 31,
2017 | | | Avenue | | Avenue Therapeutics, Inc. 2015 Stock Plan | | | 2,000,000 | | | 1,115,000 | | | Caelum | | Caelum Biosciences Inc. 2017 Incentive Plan | | | 2,000,000 | | | 125,002 | | | Cellvation | | Cellvation Inc. 2016 Incentive Plan | | | 2,000,000 | | | 300,000 | | | Checkpoint | | Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan | | | 5,000,000 | | | 2,961,697 | | | Cyprium | | Cyprium Therapeutics, Inc. 2017 Stock Plan | | | 2,000,000 | | | 2,000,000 | | | Helocyte | | DiaVax Biosciences, Inc. 2015 Incentive Plan | | | 2,000,000 | | | 341,667 | | | Journey | | Journey Medical Corporation 2015 Stock Plan | | | 3,000,000 | | | 614,792 | | | Mustang | | Mustang Bio, Inc. 2016 Incentive Plan | | | 2,000,000 | | | 444,325 | | | Tamid | | FBIO Acquisition Corp. V 2017 Incentive Plan | | | 2,000,000 | | | 1,600,000 | |
|
| Schedule of Share-based Compensation, Activity |
The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2017, 2016 and 2015: | | | For the Years Ended December 31, | | | ($ in thousands) | | 2017 | | 2016 | | 2015 | | | Employee awards | | $ | 6,606 | | $ | 7,386 | | $ | 8,130 | | | Executive awards of Fortress Companies’ stock | | | - | | | - | | | 2,228 | | | Non-employee awards | | | 83 | | | 33 | | | 33 | | | Fortress Companies: | | | | | | | | | | | | Avenue | | | 604 | | | 28 | | | 51 | | | Caelum | | | 595 | | | - | | | - | | | Cellvation | | | 31 | | | 7 | | | - | | | Checkpoint | | | 3,118 | | | 3,867 | | | 3,252 | | | Helocyte | | | 128 | | | 250 | | | - | | | JMC | | | 224 | | | 515 | | | 597 | | | Mustang | | | 2,013 | | | - | | | - | | | Tamid | | | 1 | | | - | | | - | | | National | | | 602 | | | 42 | | | - | | | Total stock-based compensation expense | | $ | 14,005 | | $ | 12,128 | | $ | 14,291 | |
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable |
The following table summarizes Fortress stock option activities excluding activities related to Fortress Companies: | | | Number of
shares | | Weighted
average
exercise price | | Total
weighted
average
intrinsic
value | | Weighted
average
remaining
contractual
life (years) | | | Options vested and expected to vest at December 31, 2015 | | | 1,779,365 | | $ | 4.37 | | $ | 666,396 | | | 6.32 | | | Forfeited | | | (648,864) | | | 0.51 | | | - | | | - | | | Options vested and expected to vest at December 31, 2016 | | | 1,130,501 | | | 3.73 | | | 602,451 | | | 4.93 | | | Exercised | | | (20,000) | | | 1.37 | | | 52,400 | | | - | | | Exercisable as of December 31, 2016 | | | 1,110,501 | | $ | 3.78 | | $ | 1,351,080 | | | 3.95 | | | Options vested and expected to vest at December 31, 2017 | | | 1,085,501 | | $ | 3.75 | | $ | 1,351,080 | | | 3.93 | |
|
| Nonvested Restricted Stock Shares Activity |
The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies: | | | Number of shares | | Weighted
average
grant price | | | Unvested balance at December 31, 2015 | | | 8,757,935 | | $ | 2.47 | | | Restricted stock granted | | | 1,240,868 | | | 2.77 | | | Restricted stock cancelled | | | (33,333) | | | 2.69 | | | Restricted stock vested | | | (173,333) | | | 2.73 | | | Restricted stock units granted | | | 641,000 | | | 2.93 | | | Restricted stock units cancelled | | | (111,750) | | | 3.58 | | | Restricted stock units vested | | | (227,292) | | | 3.56 | | | Unvested balance at December 31, 2016 | | | 10,094,095 | | $ | 2.49 | | | Restricted stock granted | | | 1,325,396 | | | 2.70 | | | Restricted stock vested | | | (213,333) | | | 2.75 | | | Restricted stock units granted | | | 1,128,750 | | | 4.17 | | | Restricted stock units forfeited | | | (15,000) | | | 2.98 | | | Restricted stock units vested | | | (445,874) | | | 3.50 | | | Unvested balance at December 31, 2017 | | | 11,874,034 | | $ | 2.63 | |
|
| Schedule of Warrant Activities |
The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: | | | Number of
shares | | Weighted
average
exercise price | | Total
weighted
average
intrinsic
value | | Weighted
average
remaining
contractual
life (years) | | | Outstanding as of December 31, 2015 | | | 569,835 | | $ | 6.31 | | $ | 120,700 | | | 1.84 | | | Granted | | | 1,880,000 | | | 3.00 | | | - | | | 5.65 | | | Expired | | | (161,382) | | | 6.30 | | | - | | | - | | | Exercised (*) | | | (25,000) | | | 1.37 | | | 33,250 | | | - | | | Outstanding as of December 31, 2016 | | | 2,263,453 | | $ | 3.62 | | $ | 79,800 | | | 4.74 | | | Granted | | | 816,180 | | | 3.84 | | | 260,380 | | | 4.87 | | | Forfeited | | | (305,444) | | | 7.07 | | | - | | | - | | | Outstanding as of December 31, 2017 | | | 2,774,189 | | $ | 3.30 | | $ | 2,204,530 | | | 4.47 | | | Exercisable as of December 31, 2017 | | | 869,189 | | $ | 3.96 | | $ | 318,580 | | | 4.05 | | (*) cashless
|
| Schedule of Fair Value of Separate Accounts by Major Category of Investment |
On July 15, 2015 and on October 31, 2016, the following grants of 500,000 warrants each were made to Dr. Rosenwald and Mr. Weiss for their services to the Company: | 2015 | | Warrant
Shares | | Risk Free
Rate | | Volatility | | Life | | Exercise
price | | Fair Value | | | Mustang | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.147 | | $ | 135,000 | | | Checkpoint | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.129 | | $ | 118,000 | | | Avenue | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.146 | | $ | 134,000 | | | CNDO SO | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 1.190 | | $ | 1,091,000 | | | Helocyte | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.097 | | $ | 89,000 | | | JMC | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.650 | | $ | 596,000 | | | Escala | | | 1,000,000 | | | 2.36 | % | | 106.11 | % | | 10 | | $ | 0.071 | | $ | 65,000 | | | | | | | | | | | | | | | | | | | | | | | | 2016 | | | | | | | | | | | | | | | | | | | | | Cellvation | | | 1,000,000 | | | 2.86 | % | | 70 | % | | 9 | | $ | 0.024 | | $ | 18,000 | |
Beginning in 2017, the LTIP equity interest grants were made in the form of stock. During the year ended December 31, 2017, Mr. Weiss and Dr. Rosenwald received, for their services to the Company, stock awards of 500,000 shares representing 5% of the ownership in the following entities: | | | | | | Risk Free | | | | | Discount for
Lack of | | Exercise | | | | | | 2017 | | Stock Shares | | Rate | | Volatility | | Marketability | | price | | Fair Value | | | Aevitas | | | 1,000,000 | | | 1.92 | | | 79.8 | % | | 42.6 | % | $ | 0.020 | | $ | 20,000 | | | Caelum | | | 1,000,000 | | | 1.93 | | | 70.0 | % | | 49.5 | % | $ | 0.028 | | $ | 28,000 | | | Cyprium | | | 1,000,000 | | | 1.92 | | | 84.3 | % | | 44.2 | % | $ | 0.004 | | $ | 4,000 | | | Acquisition Corp. III | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | | | Acquisition Corp. IV | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | | | Tamid | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | | | Acquisition Corp. VI | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | | | Acquisition Corp. VII | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | | | Acquisition Corp. VIII | | | 1,000,000 | | | 1.92 | | | 83.9 | % | | 44.0 | % | $ | 0.007 | | $ | 7,000 | |
|